Retroperitoneal liposarcoma presents distinct management challenges shaped by its anatomical setting and histological composition. Careful assessment of tumour resectability and tissue characteristics drives the choice of treatment strategy.
This protocol applies to retroperitoneal liposarcoma. The differentiation between the well-differentiated and dedifferentiated components of the tumour is critical to surgical decision-making and determines the extent and sequencing of treatment.
When the tumour is technically unresectable or borderline resectable, a neoadjuvant strategy aimed at downstaging the tumour prior to surgery may be considered. The approach draws on systemic and locoregional treatment modalities — the specific options, their sequencing, and the criteria that govern their selection are detailed in the full protocol.
DOI: 10.1016/j.annonc.2021.07.006
Specific appreciation of the well-differentiated versus the dedifferentiated component(s) of liposarcoma is critical to surgical decision making.
Neoadjuvant treatment, in the form of ChT, external beam RT (EBRT), regional hyperthermia or combinations, can be considered in the case of technically unresectable/ borderline resectable, i.e. RPS that could be surgically converted by downsizing, and in chemosensitive histologies such as synovial sarcoma.
View source ↗